ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)64909-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)64909-1/fulltext
Title :
ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64909-1&doi=10.1016/S1098-3015(10)64909-1
First page :
Section Title :
Open access? :
No
Section Order :
67